Keyphrases
Prostate Cancer
87%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
70%
Advanced Prostate Cancer
58%
Bladder Cancer
51%
Minimal Residual Disease
50%
Overall Survival
50%
Clear Cell Renal Cell Carcinoma (ccRCC)
37%
Muscle-invasive Bladder Cancer
37%
Abiraterone
37%
Enzalutamide
33%
Chemotherapy
31%
Tumor
30%
Tumor DNA
27%
Curative Intent
26%
DNA Detection
25%
Radical Cystectomy
25%
Essential Pathway
25%
CDK12
25%
Transcriptomic Characterization
25%
Epigenetics
25%
Progression Markers
25%
Survival Outcomes
25%
Comorbid Diseases
25%
Upper Tract Urothelial Carcinoma
22%
Cancer Patients
19%
Carboplatin
18%
Clinical Trial Development
16%
PARP Inhibitor (PARPi)
16%
Circulating Tumor DNA (ctDNA)
15%
Positron Emission Tomography-computed Tomography (PET-CT)
15%
Urine Cell-free DNA
15%
Treatment Outcome
15%
Multi-omics
15%
Radiotherapy Alone
15%
Proteogenomics
15%
Tumor Evolution
15%
Single-nucleus RNA Sequencing
15%
Spatial Transcriptomics
15%
BRCA1, BRCA2
15%
Clinical Trial Design
14%
Solid Tumors
14%
Metastatic Urothelial Carcinoma
14%
Multivariable
14%
Chemoradiotherapy
13%
Liquid Biopsy
12%
Combination Immunotherapy
12%
Cyclin-dependent Kinase 12
12%
Metastatic Urothelial Cancer
12%
Tumor Survival
12%
Clinical Proteomic Tumor Analysis Consortium
12%
Medicine and Dentistry
Prostate Cancer
83%
Neoplasm
69%
Minimal Residual Disease
50%
Overall Survival
46%
Castration Resistant Prostate Cancer
39%
Muscle Invasive Bladder Cancer
37%
Bladder Cancer
35%
Diseases
33%
Radiation Therapy
30%
Transitional Cell Carcinoma
29%
Bladder
28%
Immunotherapy
28%
Cohort Analysis
27%
Cystectomy
25%
Chemoradiotherapy
25%
Clear Cell Renal Cell Carcinoma
25%
Urothelial Cancer
25%
Bladder Tumor
22%
Malignant Neoplasm
21%
Immune Checkpoint Blockade
18%
Circulating Tumor DNA
17%
Positron Emission Tomography-Computed Tomography
16%
Cisplatin
15%
Cell-Free DNA
14%
Liquid Biopsy
14%
Homologous Recombination
14%
Clinical Trial
13%
Tamsulosin
12%
Enzalutamide
12%
Abiraterone
12%
Solid Malignant Neoplasm
12%
Cyclin-Dependent Kinase
12%
Coronary Artery Calcification
12%
Therapy Delay
12%
Extrapulmonary Tuberculosis
12%
4 Iodo 2,5 Dimethoxyamphetamine
12%
PARP1
12%
Brain Metastasis
12%
Recombination Repair
12%
Transcriptomics
12%
Cardiovascular Risk
12%
Robot-Assisted Prostatectomy
12%
Lung Tuberculosis
12%
Gene Expression
12%
Carcinomatous Peritonitis
12%
Crohn's Disease
12%
Otitis Media
12%
Avelumab
12%
Proteomics
12%
Proteogenomics
12%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Overall Survival
52%
Abiraterone
38%
Castration Resistant Prostate Cancer
37%
Enzalutamide
33%
Diseases
33%
Bladder Cancer
33%
Malignant Neoplasm
31%
Clinical Trial
28%
Neoplasm
25%
Renal Cell Carcinoma
25%
Chemoradiation Therapy
25%
Immunotherapy
25%
Chemotherapy
24%
Bladder Tumor
22%
Adverse Event
18%
Transitional Cell Carcinoma
18%
Cardiovascular Risk
15%
Clinical Trial Design
14%
Prostate Specific Antigen
14%
Prostate Disease
12%
Extrapulmonary Tuberculosis
12%
Minimal Residual Disease
12%
Myeloma
12%
Bone Metastasis
12%
Zoledronic Acid
12%
Coronary Artery Calcification
12%
Tamsulosin
12%
Multiple Myeloma
12%
Cyclin Dependent Kinase
12%
Muscle Invasive Bladder Cancer
12%
Pazopanib
12%
Crohn's Disease
12%
Lung Tuberculosis
12%
Otitis Media
12%
Endocrine Therapy
12%
FDA Adverse Event Reporting System
12%
Cardiovascular Disease
10%
Gonadorelin Antagonist
10%
Recurrent Disease
9%
Metastatic Breast Cancer
8%
Monotherapy
7%
Gonadorelin Agonist
7%
Androgen Receptor
7%
Congestive Heart Failure
7%
Night Sweat
6%
Otorrhea
6%
CA 50 Antigen
6%
Non Muscle Invasive Bladder Cancer
6%
Nucleic Acid
6%